Reply: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac

References 

1. Bucci FA, Waterbury LD, Amico LM. Prostaglandin E₂ inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol. 2007;144:146–147
   • Abstract
   • Full Text
   • Full-Text PDF (157 KB)
   • CrossRef
2. Walters T. Prostaglandin E₂ inhibition and aqueous concentration of ketorolac 0.4% and nepafenac 0.1% in patients undergoing phacoemulsification. [letter] Am J Ophthalmol. 2007;144:978–979reply by FA Bucci Jr, 979–980
   • Full Text
   • Full-Text PDF (50 KB)
   • CrossRef
3. Fleisher LN, McGahan MC. Time course for prostaglandin synthesis by rabbit lens during endotoxin-induced ocular inflammation. Curr Eye Res. 1986;5:629–634
   • MEDLINE
   • CrossRef
4. Csukas S, Paterson CA, Brown K, Bhattacherjee P. Time course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxin. Invest Ophthalmol Vis Sci. 1990;31:382–387Available at: http://www.iovs.org/cgi/reprint/31/2/382Accessed May 22, 2008
5. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371–384
   • MEDLINE
   • CrossRef
6. Nardi M, Lobo C, Bereczki A, Cano J, Zagato E, Potts S, et al. Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery; for the International C-04-65 Study Group. Clin Ophthalmol. 2007;1(4):527–533